Abstract
We present a female patient with a history of systolic heart failure with an ejection fraction of 25–30%, and unprovoked pulmonary embolism on extended anticoagulation therapy with rivaroxaban who underwent a pericardial window for cardiac tamponade due to hemopericardium in the setting of direct oral anticoagulant (DOAC). The rivaroxaban was held following the pericardial window, and she experienced another episode of pulmonary embolism before the rivaroxaban could be restarted. Currently, there are no guidelines on when to restart anticoagulation postpericardial window for DOAC-associated hemopericardium. Studies are needed to help solve this dilemma.
Plain language summary
We present a female patient with a history of systolic heart failure which means their left ventricle was unable to pump blood efficiently. They also have a history of an unprovoked disruption in the flow of blood in the pulmonary arteries or its branches, known as a pulmonary embolism. The patient was on direct oral anticoagulation medication to thin their blood, promoting efficient blood flow and minimizing the risk of clots and blockages. While on this medication, the patient developed a significant collection of blood around the heart, so the medication was withheld and the blood collection was drained. She developed another episode of pulmonary embolism before the medication could be restarted. Healthcare providers need guidance on when to restart anticoagulation medications in these types of patients.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. . Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge. J. Thromb. Thrombolysis 45(1), 51–55 (2018).
- 2. . Comparing mortality in patients with atrial fibrillation who are receiving a direct-acting oral anticoagulant or warfarin: a meta-analysis of randomized trials. J. Thromb. Haemost. 12(9), 1419–1424 (2014).
- 3. Antithrombotic therapy for VTE disease. Chest 149(2), 315–352 (2016).
- 4. . DOACs vs Vitamin K antagonists: a comparison of phase III clinical trials and a prescriber support tool. Open access maced. J. Med. Sci. 7(7), 1226–1232 (2019).
- 5. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139–1151 (2009).
- 6. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10), 883–891 (2011).
- 7. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365(11), 981–992 (2011).
- 8. Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 369(22), 2093–2104 (2013).
- 9. . A systematic review of patient-reported outcomes associated with the use of direct-acting oral anticoagulants. Br. J. Clin. Pharmacol. 85(12), 2652–2667 (2019).
- 10. . Medication taking behaviors in patients taking warfarin versus direct oral anticoagulants: a systematic review. Expert Rev. Cardiovasc. Ther. 17(6), 427–434 (2019). •• Benefits of direct oral anticoagulants over warfarin.
- 11. Hemopericardium in the setting of direct oral anticoagulant use: an updated systematic review. Cardiovasc. Revasc. Med. 39, 73–83 (2021).
- 12. Incidence and management of hemopericardium: impact of changing trends in invasive cardiology. Mayo Clin. Proc. 93(8), 1086–1095 (2018).
- 13. . Isolated hemopericardium associated with rivaroxaban: first case report. Pharmacotherapy 34(9), e169–e172 (2014).
- 14. . Hemorrhagic cardiac tamponade associated with apixaban: a case report and systematic review of literature. Cardiovasc. Revasc. Med. 20(Suppl. 11), 15–20 (2019).
- 15. . Hemopericardium with subsequent cardiac tamponade secondary to rivaroxaban treatment: a case report. Eur. Heart J. Case Rep. 5(1), ytaa482 (2020).
- 16. . Hemopericardium with tamponade following rivaroxaban administration and its attenuation by Cyp3A4 inhibitors. Bayl. Univ. Med. Cent. Proc. 29(4), 414–415 (2016).
- 17. . Life-threatening hemopericardium associated with rivaroxaban. Case Rep. Cardiol. 2017, 4691325 (2017).
- 18. Hemopericardium in the setting of direct oral anticoagulant use: an updated systematic review. Cardiovasc. Revasc. Med. 39, 73–83 (2021).
- 19. . How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 120(15), 2954–2962 (2012). • Perioperative management of direct oral anticoagulants (DOACs).
- 20. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ 366, l4363 (2019). • Study discussing the risk of early interruption of anticoagulation in patients on extended DOAC therapy.
- 21. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [published correction appears in Chest]. Chest 142(6), 1698–1704 (2012). •• Indications for inferior vena cava filter placement.
- 22. Endovascular venous interventions – a state-of-the-art review. Curr. Probl. Cardiol. 48(3), 101534 (2023). • Comprehensive review of endovascular interventions such as an inferior vena cava filter for deep vein thrombosis.
